Inhibrx Biosciences shares are trading lower. The company announced primary endpoint results from the Phase 2 HexAgon study of INBRX-106, an OX40 agonist, combined with pembrolizumab versus pembrolizumab alone in PD-L1 positive head and neck squamous cell carcinoma.